Turning to Wall Street, the analysts’ consensus rating for Praxis Precision Medicines is Strong Buy, based on 10 Buy and a single Sell rating over the past three months. With that comes an average ...

Shares of biopharmaceutical company Praxis Precision Medicines Inc. are soaring, boosted by the successful trial of a new drug to treat movement disorders. The drug, ulixacaltamide, targets essential ...

Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of ...

Praxis Precision Medicines Inc. (NASDAQ: PRAX) is one of the Reddit stocks that will go to the moon. On October 16, Praxis ...

Praxis Precision Medicines (PRAX) stock surges as its movement disorder therapy ulixacaltamide succeeds in two Phase 3 trials in essential tremor. Read more here.

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks.

Praxis Precision soared to a new all-time high on Thursday, more than tripling its share price during the intraday session, ...

On Tuesday, Praxis Precision Medicines Inc. (NASDAQ:PRAX) released topline results for its EMBOLD Phase 2 proof-of-concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic ...

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

On Friday, Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released interim data from Study 1 of the Essential3 program of ulixacaltamide in essential tremor (ET). The Independent Data Monitoring ...

BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...